Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional IL-2 and Radiotherapy in Refractory Metastatic NSCLC
NCT03224871Phase 1Completed
- Sponsor
- University of California, Davis
- Start
- Aug 2017
- Primary completion
- Jan 2020
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of aldesleukin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of California, Davis. Primary endpoint: Dose Limiting Toxicity at 12 months. Started Aug 2017; status: completed.
02
Drugs
aldesleukin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03224871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03224871.